Rakesh Jain, MD
Interventional Cardiology · Richmond, VANPI 1013992874
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,930 of the $5,898 with a category attached, or 66.6%. Teva Pharmaceuticals USA, Inc. accounts for 67.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $3,962 and has fallen 99.1% since, to $37 in 2024.
Across 7 payments — averaging $842.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$4K
- AbbVie$2K
- Axsome Therapeutics, Inc.$32
- Regeneron Healthcare Solutions, Inc.$12
- E.r. Squibb & Sons, L.L.C.$12
Across 3 payments — averaging $108,333 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$325K
What the payments were for
- Consulting fees$3,93067%
- Speaking & faculty fees$1,87532%
- Food & beverage$811%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 3 | $3,967 |
| AbbVie | 1 | $1,875 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,898 in reported general payments places this provider in the 55th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 128 | $108,028 |
| EntrestoSacubitril/Valsartan | 33 | $28,900 |
| Repatha SureclickEvolocumab | 15 | $12,653 |
| Metoprolol Succinate | 109 | $1,113 |
| Amlodipine Besylate | 140 | $1,029 |
| Losartan Potassium | 122 | $1,018 |
| Atorvastatin Calcium | 144 | $1,001 |
| Carvedilol | 131 | $773 |
| Nifedipine ErNifedipine | 18 | $716 |
| Potassium Chloride | 33 | $557 |
| Lisinopril | 96 | $482 |
| Furosemide | 70 | $480 |
| Torsemide | 19 | $446 |
| ClopidogrelClopidogrel Bisulfate | 64 | $396 |
| Rosuvastatin Calcium | 50 | $372 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Richmond
- Gansevoort DunningtonRichmond$440K
- Matthew ChungRichmond$75K
- Ashwani KumarRichmond$35K
- Brinder KandaRichmond$34K
- James GarnettRichmond$19K
- Barbara LawsonRichmond$17K
- John PosenauRichmond$11K
- Michael ArcareseRichmond$10K
- Sam DowRichmond$10K
- Deepak TalrejaVirginia Beach$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.